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LETTERS TO THE EDITOR 161and placebo (3). These results showed that the lung bio-
availability of CFC fluticasone propionate was greater
(P50?05) than the HFA formulation for both overnight
urinary cortisol corrected for creatinine. 1?9-fold (95% CI
1?2–3?2) as well as for early morning urinary cortisol
corrected for creatinine: 1?8-fold (95% CI 1.1 – 2?8).
Moreover, for all three doses together there were signifi-
cantly (P50?001) more individual low values for overnight
urinary cortisol excretion5 10 nmol 10 h71 with the CFC
formulation (31%) compared with the HFA formulation
(15%), or compared to placebo (0%). It is also curious that
Kunka et al. chose not to cite this article in this paper in
their list of references, particularly as our results contradict
their own findings.
In view of the discrepancies between the single dose
pharmacokinetic and pharmacodynamic data of Kunka
et al., along with previous chronic dosing data suggesting
differences in lung bio-availability between the HFA and
CFC formulations, one would have to cast serious doubts
on the validity of the conclusions of Kunka et al. that the
two formulations exhibit similar lung deposition and no
difference in systemic exposure at microgram equivalent
doses.
B. J. LIPWORTH
Asthma and Allergy Research Group,
Department of Clinical Pharmacology,
Ninewells Hospital and Medical School,
University of Dundee,
Dundee, DD1 9SY, U.K.
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Dear editor,
Response to letter from Professor B. J.
Lipworth Re: Paper by Kunka et al.
[Respir Med 2000; 94 (Suppl. B):
S10–S16]Dr Lipworth’s comments focus on urinary cortisol data he
presented in a letter to another journal (1). We are notsurprised that findings based on cortisol do not agree with
our measurements based upon plasma fluticasone propio-
nate (FP) AUC data (2). This is due to a number of factors
including the nonlinear sigmoid relationship between these
two variables (3). Consequently, it has been shown that
cortisol measurements alone cannot be used to reliably
quantify the systemic exposure to corticosteroids and direct
pharmacokinetic measurements should always be used (4).
In addition the type of cortisol data cited by Dr Lipworth
(1) was not based on robust methodology. Early morning
and overnight urinary cortisol requiring correction for
creatinine are indirect measurements and have not been
validated as a means of comparing the bio-availability of
corticosteroids in healthy subjects (5,6). The imprecision
and variability in these parameters is high and they have
not been shown to accurately predict the degree of
corticosteroid systemic exposure as assessed by direct
pharmacokinetic measurements (4). Correction for creati-
nine is applied to account for incomplete urine collections,
but was not required in our study because urine was
collected for a full 24-h period in closely supervised
institutionalized subjects (2). Furthermore, since the
relationship between systemic exposure to corticosteroids
and changes in cortisol is described by a sigmoid curve, the
dose range selected determines the position on the curve
and whether the change in cortisol is smaller or larger than
the accompanying change in corticosteroid plasma AUC
(4). The consequence of this is that in comparing the
relative effects on cortisol for two inhaled formulations the
difference observed is highly dependent on the doses
selected and the study design. This is illustrated in the data
cited by Dr Lipworth (1) where cortisol measurements were
not able to detect a difference when the dose doubled from
250mg b.i.d. to 500 mg b.i.d. There were also no significant
differences found between the HFA and CFC formulations
at two of the three dose levels (250 mg b.i.d. and 2000 mg
b.i.d.) and little evidence of dose proportionality. Although
the study was described as placebo-controlled and single-
blind (1) it is dicult to see how this could be accomplished
without the use of placebo inhalers and using an escalating-
dose design. In the other reference cited the studies were of
similar design, creatinine-corrected overnight cortisol ex-
cretion and morning cortisol were used to support
conclusions that also do not agree with pharmacokinetic
data. Lung deposition was claimed to differ by five-fold for
FP MDI plus spacer compared to a dry powder inhaler and
two-fold for FP MDI plus spacer compared to FP MDI
without spacer (7). These conclusions are unlikely for the
following reasons. Firstly, although a spacer removes larger
particles of FP and reduces oropharyngeal deposition, the
respirable FPM dose is essentially unchanged (8). Secondly,
the absolute bio-availability for the FP Diskus1 dry
powder inhaler has been reported as 17% (95% CI: 14-
20%) based on pharmacokinetic data (9). Therefore, a five-
fold increase would imply that 100% lung deposition could
be attained with an MDI plus spacer, whereas only 20%
deposition has been reported (10). The conclusions from
our study (2), of similar lung deposition and systemic
exposure for FP CFC and HFA MDIs, have been
confirmed in another report (11) that compared FP plasma
162 LETTERS TO THE EDITORAUCs after inhaled and intravenous dosing in the same
subjects. We are therefore of the opinion that pharmaco-
kinetic data are more reliable and that cortisol measure-
ments alone cannot be used to accurately quantify and
compare the systemic exposure to corticosteroids.
Multiple dosing of inhaled corticosteroids can also
produce greater effects on cortisol than single doses (13)
but this is not related to tissue partitioning or the volume of
distribution as suggested by Dr Lipworth. For all the
commonly prescribed inhaled corticosteroids the volume of
distribution is measured in hundreds of litres (14), the
highest value (424 l) is for beclomethasone-17-monopro-
pionate (15). The volume of distribution determines the
partitioning of the drug between plasma and tissues, but
since these values are large compared to the volume of
plasma ( 3l ) the majority of the absorbed drug (97–99%)
will be distributed to the tissue for all commonly prescribed
inhaled corticosteroids. Our aim was to compare the
formulations. This could have been achieved using a
multiple dose design giving an AUC and Cmax that would
be 1?5 times higher (12) than a single dose study for both
formulations, but leading to the same conclusions. Even if
the cortisol changes were significantly greater after multiple
dosing compared to single dosing in healthy subjects, this
has no clinical relevance to the cortisol changes seen in
patients as systemic exposure to FP and cortisol changes
are reduced in asthamatics compared to healthy subjects
(10,16).
In our study we used a specific and sensitive assay for FP
in plasma (2) and showed a dose-proportional increase in
FP plasma AUC between the strengths of the HFA inhalers
(50, 125 and 250 mg) and two strengths of CFC inhaler (125
and 250 mg), both in terms of the nominal dose and fine
particle mass (FPM) dose. The pharmacokinetic data were
also used to assess the relative risk of systemic effects for FP
HFA and CFC MDIs. Twenty-four-hour urinary cortisol
collections were also included to put any differences in
systemic exposure into a pharmacodynamic context. No
corresponding changes in cortisol were seen (2). Dr
Lipworth points out that serial plasma cortisol measure-
ments can be less variable than urinary cortisol data, but
this was not done in his study (1). In our study the reason
this measurement was not included was the need for a large
additional blood collection due to a five way cross-over
design. However, our study included 23 subjects and was
adequately powered to detect differences in 24-h urinary
cortisol excretion and FP plasma AUC, this is reflected in
the tight confidence intervals (2) and contrasts with the
variable data cited by Dr Lipworth (1).
Our conclusion is that in the study cited by Lipworth (1),
changes in early morning and overnight urinary cortisol
requiring creatinine correction, in 16 healthy subjects, were
claimed to support lack of clinical equivalence. This claim,
was based on indirect measurements using a highly
variable, inconsistent and unvalidated methodology. Our
study, using a specific drug assay in 23 subjects, demon-
strated similar systemic exposure and no increased risk of
systemic effects for HFA FP compared to CFC FP and is
supported by other pharmacokinetic data (9). The equiva-
lent clinical ecacy for HFA FP and CFC FP is a separateissue, which is not predicted by cortisol excretion, but has
been demonstrated by clinical studies in 911 asthmatic
patients (17–19).
P. T. DALEY-YATES* AND R. L. KUNKA{
*Clinical Pharmacology, Glaxo Welcome R&D,
Greenford, UB6 OHE, U.K.
{Clinical Pharmaacology, Glaxo Welcome Inc.,
Research Triangle Park, North Carolina, U.S.A.
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